Triclabendazole

Source: Wikipedia, the free encyclopedia.

Triclabendazole
Clinical data
Trade namesFasinex, Egaten, others
AHFS/Drugs.comMonograph
MedlinePlusa619048
License data
QP52AC01 (WHO)
Legal status
Legal status
Pharmacokinetic data
MetabolismOxidation to sulfone and sulfoxide metabolites
Elimination half-life22–24 hours
ExcretionFeces (>95%), urine (2%), milk (<1%)
Identifiers
  • 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
JSmol)
Melting point175 to 176 °C (347 to 349 °F)
  • CSc3nc2cc(Cl)c(Oc1cccc(Cl)c1Cl)cc2[nH]3
  • InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19) checkY
  • Key:NQPDXQQQCQDHHW-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat

fascioliasis and paragonimiasis.[1] It is very effective for both conditions.[1] Treatment in hospital may be required.[1] It is taken by mouth with typically one or two doses being required.[1]

Side effects are generally few, but can include abdominal pain and headaches.

Triclabendazole was approved for medical use in the United States in 2019.[3][4] It is on the World Health Organization's List of Essential Medicines.[5] For human use, it can be obtained from the World Health Organization.[2] It is also used in animals.[6]

Chemistry

It is a member of the

microtubules.[citation needed
]

History

Since late 1990s, triclabendazole became available as a

roundworms and ectoparasites, as well.[citation needed
]

Fasinex is a brand name for veterinary use while Egaten is a brand name for human use.[citation needed]

References

Further reading